Your Article Summary
See Latest ArticlesAngiotech pharmaceuticals announces fda approval of nextgeneration taxus liberte atom stent
Angiotech Pharmaceuticals, 05/28/09
Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation has received approval from the U.S. Food and Drug Administration to market its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Genentech, 12/08/09
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09
Genzyme Begins Shipping Newly Produced Cerezyme from Allston Plant
Genzyme, 12/02/09